<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04652544</url>
  </required_header>
  <id_info>
    <org_study_id>2020-06</org_study_id>
    <nct_id>NCT04652544</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in Individuals With a Chronic Spinal Cord Injury</brief_title>
  <official_title>Vitamin D Supplementation in Individuals With a Chronic Spinal Cord Injury - a Placebo-controlled Randomized Double-blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Paraplegic Centre Nottwil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Paraplegic Centre Nottwil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this placebo-controlled randomized double-blinded study is to&#xD;
      investigate the effect of vitamin D supplementation on vitamin D status (25(OH)D&#xD;
      concentration in the blood) among individuals with a chronic spinal cord injury (SCI).&#xD;
      Further, the effects of vitamin D supplementation on several other parameters (e.g. bone&#xD;
      density and mood) are investigated, which could reveal positive secondary effects of&#xD;
      supplementation that are especially relevant for clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the influence of vitamin D supplementation among&#xD;
      individuals with chronic SCI. The primary aim is to study whether different dosages (24'000&#xD;
      IU/month or 48'000 IU/month) of vitamin D supplementation over 12 months will lead to&#xD;
      differences in vitamin D status as well as differences in several other outcomes. The use of&#xD;
      a placebo group supports the evaluation of dose-response effects of vitamin D supplementation&#xD;
      on the primary outcome (vitamin D status) and secondary outcomes (including bone density and&#xD;
      mood) that are not only supported by randomized controlled trial standards but also&#xD;
      informative in clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants having a vitamin D status ≤ 75 nmol/L at baseline, will be randomly assigned to one of the three intervention groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitamin D status</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Serum levels of 25(OH)D in nmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>At baseline and after 12 months</time_frame>
    <description>Measurements of the forearm (radius), hip (femoral neck) and knee (distal femur and proximal tibia) will be performed using dual-energy X-ray absorptiometry (DXA) scans. T-values will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>At 0, 3, 6, 9, 12 months</time_frame>
    <description>Assessed by the Hospital Anxiety and Depression Scale (HADS) questionnaire, using a 4-step scale (1-4) with a total range of 14-56 and higher scores indicating worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>At 0, 3, 6, 9, 12 months</time_frame>
    <description>Assessed by the Fatigue Severity Scale (FSS) questionnaire, using a 8-step scale (1-7) with total range 9-63 and higher scores indicating worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic pain</measure>
    <time_frame>At 0, 3, 6, 9, 12 months</time_frame>
    <description>The occurrence of pain since the last visit is assessed by one question of the SCI Secondary Conditions Scale (Kalpakjian, Scelza et al. 2007), providing a five-step rating (0-4) with a higher score indicating a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recent pain</measure>
    <time_frame>At 0, 3, 6, 9, 12 months</time_frame>
    <description>The occurrence, kind, location and interference of pain during the last week is assessed using questions of the adapted version of the International SCI Pain Basic Data Set (Widerström-Noga, Biering-Sørensen et al. 2008). The interference of pain is measured on a 11-step scale (0-10), with total range 0-30 and higher scores indicating worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure ulcers</measure>
    <time_frame>At 0, 3, 6, 9, 12 months</time_frame>
    <description>The occurrence, localization and severity of pressure ulcers is assessed by the exact questions of the first-wave questionnaire of the Swiss Spinal Cord Injury Cohort Study (SwiSCI) survey (Post, Brinkhof et al. 2011, Brinkhof, Fekete et al. 2016). The severity or grade is assessed using the European and US National Pressure Ulcer Advisory panels' (EPUAP-NPUAP) classification (National Pressure Ulcer Advisory Panel and Alliance. 2014), using a 4 point scale (1-4) and higher grades indicating worse outcomes.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>At 0, 3, 6, 9, 12 months</time_frame>
    <description>The mean of three measurements of both hands will be measured in kg.</description>
  </other_outcome>
  <other_outcome>
    <measure>Calcium status</measure>
    <time_frame>At 0, 3, 6, 9, 12 months</time_frame>
    <description>Serum levels of calcium (mmol/L) to monitor hypercalcemia.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Spinal Cord Injuries</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>&quot;Low&quot; dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One vial with 600 µg cholecalciferol (corresponding to a total of 24'000 IU vitamin D) and one vial with placebo every month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;High&quot; dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two vials with 600 µg cholecalciferol each (corresponding to a total of 48'000 IU vitamin D) every month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two vials with a placebo every month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol (Vitamin D3)</intervention_name>
    <description>Vi-De 3® Monthly Dose from Dr. Wild &amp; Co. AG (Muttenz, Switzerland) is a commercially available vitamin D3 supplement.</description>
    <arm_group_label>&quot;High&quot; dose</arm_group_label>
    <arm_group_label>&quot;Low&quot; dose</arm_group_label>
    <other_name>Vi-De 3® Monthly Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A placebo will be produced, consisting of the same ethanol solution as Vi-De 3® Monthly Dose, but without cholecalciferol.</description>
    <arm_group_label>&quot;Low&quot; dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent to the present study as documented by a signature&#xD;
&#xD;
          -  Chronic (&gt; 3 years) traumatic or non-traumatic spinal cord injury with a sub-C4-level&#xD;
             lesion&#xD;
&#xD;
          -  Wheelchair dependency during activities of daily living.&#xD;
&#xD;
          -  vitamin D status &lt;75nmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to the investigational product&#xD;
&#xD;
          -  Clinically relevant disorders,&#xD;
&#xD;
          -  Pressure ulcer grade 3 or 4,&#xD;
&#xD;
          -  Pregnancy, breastfeeding&#xD;
&#xD;
          -  Vitamin D supplementation within the last 12 months&#xD;
&#xD;
          -  Visiting a country with increased sun exposure (below the 37th parallel north) within&#xD;
             the last month before study enrolment or during the study&#xD;
&#xD;
          -  Fractures in both arms and/or both legs within the last five years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anke Scheel-Sailer, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head physician paraplegiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joëlle Flück, PhD</last_name>
    <phone>+41 41 939 66 17</phone>
    <email>joelle.flueck@paraplegie.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anneke Hertig-Godeschalk, PhD</last_name>
    <phone>+41 41 939 66 03</phone>
    <email>anneke.hertig@paraplegie.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Swiss Paraplegic Centre</name>
      <address>
        <city>Nottwil</city>
        <state>Luzern</state>
        <zip>6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joëlle Flück, PhD</last_name>
      <phone>+41 41 939 66 17</phone>
      <email>joelle.flueck@paraplegie.ch</email>
    </contact>
    <contact_backup>
      <last_name>Anneke Hertig-Godeschalk, PhD</last_name>
      <phone>+41 41 939 66 03</phone>
      <email>anneke.hertig@paraplegie.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

